Canaccord Adams downgrades NxStage Medical (Nasdaq: NXTM) from Buy to Hold and lowers its price target from $12 to $7.
This article: 124 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE